0.9009
1.92%
-0.0176
Handel nachbörslich:
.90
-0.0009
-0.10%
Ocugen Inc Aktie (OCGN) Neueste Nachrichten
Ocugen Announces European Medicines Agency Grants Orphan - GlobeNewswire
Ocugen reports positive data for OCU400, OCU410 - MSN
Ocugen Inc. stock rises Wednesday, outperforms market - MarketWatch
Ocugen announces EMA granted orphan medicinal product designation for OCU410ST - TipRanks
Ocugen Advances Gene Therapy and Financial Strategies in Q3 2024 - MSN
Ocugen's Eye Disease Drug Shows 84% Lesion Reduction, Receives EMA Orphan Status | OCGN Stock News - StockTitan
Ocugen Inc. stock falls Tuesday, underperforms market - MarketWatch
Ocugen announces positive preliminary data from OCU410 Phase 1 clinical trial for geographic atrophy - Ophthalmology Times
Ocugen announces preliminary efficacy, safety data from Phase 1/2 OCU410 trial - TipRanks
Ocugen Announces Compelling Preliminary Data for OCU410—a Single Dose Novel Modifier Gene Therapy to Treat Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration - Ocugen
Ocugen Announces Compelling Preliminary Data for OCU410—a - GlobeNewswire
Ocugen's Eye Treatment Shows 21% Disease Slowdown in Phase 1 Trial Data | OCGN Stock News - StockTitan
Ocugen Inc. stock falls Monday, underperforms market - MarketWatch
OCGN Stock: Can New Leadership Save This Biotech Company? - TipRanks
Ocugen Inc. stock falls Friday, underperforms market - MarketWatch
Ocugen Appoints Ramesh Ramachandran as Financial Officer - TipRanks
Dow Jones Transportations Average (DOWT) QuotePress Release - The Globe and Mail
TSX Venture Composite Index (JX) QuotePress Release - The Globe and Mail
TSX 60 Index (TXSX) QuotePress Release - The Globe and Mail
Nasdaq Health Care Index (IXHC) QuotePress Release - The Globe and Mail
TSX Composite Index (TXCX) QuotePress Release - The Globe and Mail
Microsoft Corp (MSFT-Q) QuotePress Release - The Globe and Mail
Ocugen: Q3 Earnings Snapshot - New Haven Register
Ocugen, Inc. (OCGN) Quarterly 10-Q Report - Quartzy
Ocugen Inc. stock rises Thursday, outperforms market - MarketWatch
Ocugen (OCGN) Reports Q3 Loss, Misses Revenue Estimates - Yahoo Finance
SEC Form 10-Q filed by Ocugen Inc. - Quantisnow
HC Wainwright Has Pessimistic View of Ocugen FY2024 Earnings - MarketBeat
Ocugen Inc. stock falls Wednesday, underperforms market - MarketWatch
Ocugen to Present Innovations at Nasdaq Clinical Showcase - TipRanks
Navigating 4 Analyst Ratings For Ocugen - Benzinga
Ocugen (NASDAQ:OCGN) Given Buy Rating at HC Wainwright - MarketBeat
Chardan Capital Reaffirms Buy Rating for Ocugen (NASDAQ:OCGN) - MarketBeat
Earnings call: Ocugen outlines progress in ophthalmology trials, financials - Investing.com
Earnings call: Ocugen outlines progress in ophthalmology trials, financials By Investing.com - Investing.com Australia
Ocugen, Inc. (NASDAQ:OCGN) Q3 2024 Earnings Call Transcript - Insider Monkey
Ocugen Inc (OCGN) Q3 2024 Earnings Call Highlights: Strategic Advances Amid Financial Challenges - Yahoo Finance
Ocugen: Progress in Gene Therapy and Financial Outlook - TipRanks
Ocugen (OCGN) Q3 2024 Earnings Call Transcript - The Motley Fool
OCGN Earnings: Ocugen’s Q3 Results Disappoint - TipRanks
Ocugen receives $30M credit facility to fund, allocate resources across company - Pennsylvania Business Report
Ocugen reports Q3 revenue $1.136M, consensus $300,000 - TipRanks
Ocugen Provides Business Update with Third Quarter 2024 Financial Results - Ocugen
Ocugen Secures $65M Financing, Extends Runway to 2026 as Gene Therapy Trials Advance | OCGN Stock News - StockTitan
Ocugen (NASDAQ:OCGN) soars 19% this week, taking one-year gains to 193% - Simply Wall St
A Preview Of Ocugen's Earnings - Benzinga
Ocugen Secures $30 Million In Debt Funding - citybiz
Ocugen Secures $30 Million in Debt Funding - Ocugen
Ocugen, Inc. Secures $30 Million in Debt Funding - Marketscreener.com
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):